These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 33032771

  • 1. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial.
    Husni ME, Kavanaugh A, Chan EKH, Peterson S, Li N, Hsia EC, Kim L, Lo KH, Harrison DD, Han C.
    Value Health; 2020 Oct; 23(10):1286-1291. PubMed ID: 33032771
    [Abstract] [Full Text] [Related]

  • 2. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
    Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P.
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
    Reveille JD, Deodhar A, Ince A, Chan EKH, Peterson S, Li N, Hsia EC, Kim L, Lo KH, Xu S, Harrison DD, Han C.
    Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
    [Abstract] [Full Text] [Related]

  • 5. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial.
    Ogdie A, Walsh JA, Chakravarty SD, Peterson S, Lo KH, Kim L, Li N, Hsia EC, Chan EKH, Kavanaugh A, Husni ME.
    Clin Rheumatol; 2021 Sep; 40(9):3667-3677. PubMed ID: 33655380
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
    Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.
    Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
    Kristensen LE, Soliman AM, Papp K, Barcomb L, Eldred A, Östör A.
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
    Kavanaugh A, Mease P.
    J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, Hsia EC.
    J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.
    Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):806-813. PubMed ID: 30980514
    [Abstract] [Full Text] [Related]

  • 20. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
    van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C, GO-RAISE investigators.
    J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.